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Background: Breast cancer places a heavy burden on the Australian healthcare system, but information about the
actual number of women living with breast cancer and their current or future health service needs is limited. We
used existing population-based data and innovative statistical methods to address this critical research question in
a well-defined geographic region.
Methods: Breast cancer data from the New South Wales (NSW) Central Cancer Registry and PIAMOD (Prevalence
and Incidence Analysis MODel) software were used to project future breast cancer prevalence in NSW. Parametric
models were fitted to incidence and survival data, and the modelled incidence and survival estimates were then
used to estimate current and future prevalence. To estimate future healthcare requirements the projected
prevalence was then divided into phases of care according to the different stages of the survivorship trajectory.
Results: The number of women in NSW living with a breast cancer diagnosis had increased from 19,305 in 1990 to
48,754 in 2007. This number is projected to increase further to 68,620 by 2017. The majority of these breast cancer
survivors will require continued monitoring (31,974) or will be long-term survivors (29,785). About 9% will require
active treatment (either initial therapy, or treatment for subsequent metastases or second cancer) and 1% will need
end of life care due to breast cancer.
Conclusions: Extrapolating these projections to the national Australian population would equate to 209,200
women living with breast cancer in Australia in 2017, many of whom will require active treatment or post-treatment
monitoring. Thus, careful planning and development of a healthcare system able to respond to this increased demand
is required.
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AustraliaBackground
Breast cancer is currently the most common cancer
among women worldwide [1], and is expected to remain
so in the foreseeable future [2,3]. In Australia, the risk of
a woman developing breast cancer before the age of 85
is 1 in 8 [4], and the number of new diagnoses is* Correspondence: xueqiny@nswcc.org.au
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unless otherwise stated.expected to continue to increase in the future [5]. Fortu-
nately however, advances in diagnosis and treatment
mean that breast cancer survival is now very high [6]:
the 5-year relative survival in Australian women was
89.4% in 2006–2010, and for those diagnosed with small
tumours (the majority of the screen-detected tumours)
5-year relative survival was over 98% [4]. As a conse-
quence of these trends of rising incidence and survival,
it is almost certain that the number of Australian
women living with breast cancer will keep increasing in
the near future. Understanding the health-care needs ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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health-care will enable better allocation of resources and
the provision of better care, and is therefore of increas-
ing importance.
Despite these predictions, there is currently only very
limited information available about breast cancer preva-
lence and the current or future health service needs of
breast cancer patients in Australia. Information available
tends to be restricted to the number of prevalent cancer
patients at a past date [7,8], which is of limited use in
predicting future health service requirements. Current
and future estimates of prevalence would be more useful
for health service planning, but as estimating cancer
prevalence is a complex process, reliant on accurate inci-
dence and survival modelling, this information is rarely
available.
Predicting future breast cancer health service needs is
further complicated by the widely varied treatment and
follow-up requirements of these women [9,10]. The
population of survivors consists of individuals with vary-
ing needs: some may be in remission (needing follow-up
care and surveillance), others may be receiving primary
treatment after initial diagnosis, while others may be re-
ceiving treatment for metastases and some may be dying
from breast cancer. Thus, estimates of cancer prevalence
for relatively homogeneous populations of survivors de-
fined by phase of the disease and who are likely to have
similar healthcare needs would be informative for health
service planning purposes. The aim of this study was to
estimate the number of women living with breast cancer
in Australia at different phases of the disease trajectory,




There were three principal activities involved in this
study: the estimation and projection of the prevalence of
breast cancer, the analysis of phase of care prevalence,
and the estimation of additional care needs for women
with disease progression or second breast cancer. The
data and methods involved in each of these activities will
be described in detail below. In brief, to estimate and
project complete prevalence of breast cancer we used the
PIAMOD software (Prevalence and Incidence Analysis
MODel) [11], with the primary input being first primary
breast cancer incidence data for cases diagnosed in
New South Wales (NSW) Australia. We then divided the
estimated complete prevalence into four phases of care ac-
cording to the different stages of the survivorship trajec-
tory, and finally incidence data for subsequent metastases
or second primary breast cancer were used to estimate the
future prevalence of such events and the associated
additional treatment requirements.Ethics statement
This study involves analysis of routinely collected data
and the records were de-identified (name, address,
date of birth had been removed) before being provided
to the research team. The ethics committee waived the
conditions for consent because it is impracticable to
seek consent as a large proportion of the individuals
would likely have moved or died since their diagnosis
of cancer which could be up to 40 years ago. Ethics
approval was obtained from the NSW Population and
Health Service Research Ethics Committee (reference
number: 2009/03/139).Estimation and projection of prevalence
The PIAMOD software was used to estimate the ob-
served prevalence (1972–2007) and project future preva-
lence (2008–2017). The PIAMOD method, described in
detail by Verdecchia et al. [11], estimates and projects
cancer prevalence and mortality through transition rate
equations that relate prevalence and mortality to inci-
dence and relative survival functions. It has been used to
estimate and project cancer prevalence for many popula-
tions [3,12-16]. The input files required by PIAMOD are
population data, all-cause mortality, cancer-specific inci-
dence and model-based survival estimates.
Incidence data for first primary female breast cancer
(ICD-O3 C50) [17] diagnosed in 1972–2007 were ex-
tracted from the NSW Central Cancer Registry database.
We included cases aged 18–84 years at diagnosis, and
excluded cases who were reported to the registry
through death certificate only, or who were first identi-
fied post-mortem. All-cause mortality data for NSW by
single year of age (up to 84 years old), and calendar year
(1972–2007), and corresponding mid-year NSW residen-
tial female population data by single year of age and cal-
endar year were obtained from the Australian Bureau of
Statistics.Modelling incidence data
Age, period and cohort (APC) models were fitted to
the incidence data using a log-linear regression model
implemented in the PIAMOD software. Nine relatively
simple models (APC101, 102, 201, 202, 103, 301, 203,
302 and 303) were fitted and the most appropriate
model was selected based on the likelihood ratio stat-
istic (LRS) combined with knowledge of the epidemi-
ology of breast cancer in Australia. The parameters of
the chosen APC model were estimated using observed
incidence for 1972–2007 and then this model was
used for forward (after 2007) and backward (before
1972) projections. The resulting fitted incidence esti-
mates were used as inputs for estimating future preva-
lence (for 2008–2017).
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Incident cases were followed up for survival status to 31
December 2007 (the most recent data available to us)
through record linkage of the cancer cases in the Cancer
Registry with the death records from the NSW Register
of Births, Deaths and Marriages and the National Death
Index. A two-step procedure was used to model the
survival data. First, relative survival was estimated and
tabulated, and then a mixture cure model was fitted to
the tabulated relative survival estimates. Relative survival
was tabulated using the Pohar Perme actuarial estimator
[18], with the classic cohort approach for five calendar
periods of diagnosis (1972–1980, 1981–1989, 1990–1995,
1996–2001, 2002–2007) and three age groups (18–49, 50–
69, and 70–84 years). A mixture cure model was fitted to
these tabulated survival data [19], and the survival
estimates obtained from the model were then projected
backward assuming a constant trend before 1972 and ex-
trapolated forwards for 2008–2017 assuming that cancer
survival trends will continue as previously observed. The
model-based estimates of survival from the mixture cure
model were used as inputs into PIAMOD for the next step
of the analysis.
Prevalence estimation
Using the PIAMOD software and the prepared input
data for the estimated incidence and survival, as well
as all-cause mortality and population data we were
then able to calculate the prevalence of first primary
breast cancer for 1972–2007 and to estimate the fu-
ture prevalence for 2008–2017. Because PIAMOD can
only provide results for closed age groups and popula-
tions, and as the available data for the older popula-
tion were grouped for those aged 85 years and
over, our prevalence estimates include cases up to age
84 years only. Population projections after 2007 were
derived in PIAMOD by assuming birth rate and mor-
tality for causes other than the specific cancer to be
stable over time [11].Figure 1 Pathways of the breast cancer survivorship journey.Validation of PIAMOD estimates
A validation of the overall estimation procedure was per-
formed using external data that were not used in the
modelling. In this case we compared the expected breast
cancer mortality derived by PIAMOD with the observed
mortality in NSW. This offers an overall validation of
both the incidence APC model and of the relative sur-
vival function. Good agreement between the expected
mortality and the observed mortality means that the
relative survival function correctly modulates the rela-
tionship between incidence and mortality.
Phase of care analysis
The estimated complete prevalence was decomposed into
four primary phases of care according to time since diag-
nosis, year of death and cause of death. These phases of
care were the initial care phase, the post-treatment moni-
toring phase, long-term survivors and the last year of life
phase, as illustrated in Figure 1.
The initial care phase was defined as care provided in
the first 12 months after diagnosis (excluding cases who
died within the first year after diagnosis). The post-treat-
ment monitoring phase was defined as the period after
initial care and before being considered a long-term
survivor.
The definition of long-term survivors varies in the lit-
erature and across cancer types. Long-term survivors are
often considered to be cancer patients who have lived
beyond 5 years after diagnosis [20-22], but the patterns
of breast cancer survival and recurrence indicate that a
longer time since diagnosis may be more appropriate
for defining long term survival of breast cancer. Thus,
similar to other researchers [23], we defined long-term
survivors as those who survived at least 10 years after
diagnosis.
The last year of life phase was defined as the last
12 months of life for those who died of breast cancer.
Cases with short survival (less than 12 months) were
considered to be in the last year of life phase. We used
Yu et al. BMC Cancer 2014, 14:936 Page 4 of 9
http://www.biomedcentral.com/1471-2407/14/936information on cause of death to identify those patients
who had died from breast cancer in a given year, and
who would therefore be in the last year of life phase of
care in that year. Future numbers of cases in the last
year of life phase for 2008–2017 were determined by the
projected breast cancer mortality trend (derived from
PIAMOD method).
In addition to these four primary phases of care, an
additional sub-phase of care (treatment for metastases/
second cancer) was created to account for cases in the
post-treatment monitoring and long-term survivor phases
who require more treatment at some point during follow-
up due to tumour spread or the development of a second
breast cancer.
Estimation and projection of metastases or second
primary breast cancer
Cases diagnosed with first primary breast cancer in
1972–2007 were followed up for subsequent metastatic
spread or second breast cancer to the end of 2007.
The development of metastases was identified using
subsequent notifications from 120 days after the first
diagnosis. As it is challenging to identify and accur-
ately distinguish between subsequent metastases and
second primaries using population datasets, and it is
likely that all such cases will require further treatment,
we combined the counts of second breast cancer and
metastatic tumours.
To estimate the number of these events in the future,
we first calculated the proportion of cases in the post-
treatment monitoring and long-term survivor phases
who presented with subsequent metastasis or second
breast cancer in 2006. We then applied this proportion
to the number of projected cases in the post-treatment
monitoring and long-term survivor phases in 2008–
2017. Those patients who survived at least one year after
the diagnosis of subsequent metastases or new primary
breast cancer were categorised into the treatment for
metastases/second cancer phase. Those who died within
one year after the diagnosis of a metastases or new pri-
mary breast cancer were considered to be in the last year
of life phase.
While each patient can contribute to more than one
phase of care over time, at any one specific point in




A total of 89,768 cases of first primary breast cancer di-
agnosed in 1972–2007 were included in the incidence
and prevalence analyses. The observed incidence trend
can be summarised with four different patterns: a rela-
tively stable period (1972–1985), a moderate increase(1986–1992), a more rapid increase (1993–1995), and
then stabilisation at a high level after 1996. During the
more stable period from 1996 there are a few fluctua-
tions in incidence, likely due to random variation and
the reduction in hormone-replacement therapy use that
occurred in Australia [24,25], and in many other devel-
oped countries [26], after the publication in 2002 of the
results of the Women’s Health Initiative randomised trial
[27]. The increased incidence between 1985 and 1996
was most likely the result of mammographic screening,
with informal screening occurring between 1985 and
1992 [28] and a population-based screening program in-
troduced in NSW from 1992 [29] (Figure 2). We plotted
the estimated incidence from nine APC models against
the observed incidence (Figure 2). Based on national
breast cancer projections [4] and more recent NSW data
[30], the APC model 303 (age3 and cohort3) was consid-
ered to be the most appropriate model with which to
project incidence for 2008–2017. This was supported by
model 303’s much smaller LRS value than those of APC
models 203 and 302 (Additional file 1), which indicates
that it is a better fitting model. Thus, estimated and pro-
jected incidence from this model (shown in Figure 3)
were used as inputs for the projection of prevalence.
Survival trends
Observed and fitted five-year breast cancer relative
survival trends over time (assuming a constant trend
before 1972 and dynamic trend after 2007) are shown
in Figure 4. It can be seen that survival improved
markedly from 1985 to 1997, followed by a slower in-
creasing trend after 1997.
Validation of PIAMOD incidence and survival estimates
Validation of the chosen APC incidence model and the
modelled relative survival estimates (Figure 5) indicates
that the APC model fitted the observed incidence data
well, which is supported by the reasonably good agree-
ment of the expected mortality with the observed
mortality.
Projected prevalence
Since 1990, the number of breast cancer survivors aged
18–84 years in NSW has increased over 150%; from
19,305 in 1990, to 35,538 in 2000, and then to 48,754 in
2007. This number is projected to increase further to
reach 68,620 in 2017, with an annual rate of increase
of 4.07% (Table 1) from 2007 to 2017. The expected
increase in the number of prevalent cases was greatest
for the oldest age group, with a 61.7% increase from
2007 to 2017. Those aged 50–69 years showed an ex-
pected 40.9% increase. The effect of population ageing
can also be seen in Table 1: the youngest age group
made up about 13% of the total prevalent cases in
Figure 2 Comparison of Age-Period-Cohort incidence models and observed age-standardised incidence rates for breast cancer in
NSW Australia.
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8% by 2017, while the proportion of prevalent cases
aged 50–69 years is expected to remain unchanged
over the same period.
Estimates of phase of care prevalence in 2017 are pre-
sented in Table 2, and show that the majority of breast
cancer survivors in 2017 will require post-treatmentFigure 3 Observed breast cancer incidence in NSW Australia for 1972monitoring (31,974) or will be long-term survivors
(29,785) who will need relatively less intensive follow-up.
Age-specific estimates indicate that the majority of the
cohort (54%) will be those aged 50–69 years and the lar-
gest single group will be those under post-treatment
monitoring aged 50–69 years, representing 28% of the
total cohort in 2017.–2007, and projected incidence for 2008–2017.
Figure 4 Comparison of fitted five-year breast cancer relative survival with observed for 1972–2007 and projected survival for
2008–2017 in NSW Australia.
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Among the 89,768 women diagnosed with first primary
breast cancer between 1972 and 2007 in NSW, there
were 13,585 women (15.1%) who developed metastatic
disease by the end of 2007. In addition, 9390 women
had a second primary breast cancer. After excluding
those who died within 12 months of the diagnosis of ei-
ther second primary or metastatic disease, 491 (2.1%)Figure 5 Comparison of fitted crude breast cancer incidence and mor
1972–2007 and projected incidence and mortality for 2008–2017 in Nwomen in post-treatment monitoring and 292 (1.5%)
long-term survivors in 2006 would require additional
treatment for their metastases or second primaries.
Thus, by applying these two estimated proportions to
the numbers of projected cases in the post-monitoring
and long-term survivor phases in 2017, it is estimated
that 1122 women would need further treatment due to
their metastases/second primaries in 2017 (Table 2).tality with observed crude incidence and mortality for
SW Australia.
Table 1 Age and year-specific estimates of prevalence of
breast cancer in NSW Australia
Year Number (%) of woman living with breast cancer
<50 years 50-69 years 70-84 years Total
2007 6204 (12.7%) 26,265 (53.9%) 16,285 (33.4%) 48,754
2011 5774 (10.5%) 29,881 (54.3%) 19,373 (35.2%) 55,028
2013 5609 (9.4%) 32,606 (54.9%) 21,185 (35.7%) 59,400
2015 5420 (8.5%) 35,062 (54.9%) 23,429 (36.7%) 63,912
2017 5292 (7.7%) 37,003 (53.9%) 26,325 (38.4%) 68,620
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By estimating current breast cancer prevalence and pro-
viding projections of this prevalence in the future, this
study fills a gap in Australian cancer research and pro-
vides a broad measure of the future health care needs of
women with breast cancer in Australia. Our projected
trends in prevalence indicate that the number of women
living with breast cancer in NSW will increase by more
than 40% from 2007 to 2017. Extrapolating these projec-
tions to the national Australian population would equate
to 209,200 women living with a previous breast cancer
diagnosis in 2017, many of whom will require treatment
or post-treatment monitoring and related care [9,10].
This information is useful for health policy makers and
health service planners, ensuring that planning for future
cancer care requirements is guided by appropriate evi-
dence. It is also relevant to clinicians who provide care
to breast cancer survivors throughout these phases, and
may be of interest to the increasing population of breast
cancer survivors.
Our prevalence estimate for 2007 in NSW using the
direct counting method (1435 per 100,000) was consist-
ent with the most updated national breast cancer preva-
lence estimate (1416 per 100,000) in 2007 reported by
the Australian Institute of Health and Welfare (AIHW)
[7]. The small difference between these estimates is
likely to be because the AIHW used 26-year prevalence
while ours was an estimate of 36-year prevalence. The
similar definition of prevalence used in our study and
the AIHW report (persons with multiple cancers beingTable 2 Estimated numbers of women living with breast canc
group
Phase of care Number (%) of breast canc
<50 years 50-
Initial care 788 (14.9%) 2
Post-treatment monitoring 3531 (66.7%) 19,
Long-term survivor 807 (15.2%) 14,
Last year of life care 77 (1.5%)
Subsequent metastases /second tumour 89 (1.7%)
Total 5292 (8.0%) 37,only counted once in the calculation) and the overall
consistency of our prevalence estimate for 2007 (the
most recent data available to us) with the most updated
national breast cancer prevalence [7] provides indirect
confirmation of our estimate. However, our study ex-
tended these results by using a valid statistical model
(PIAMOD) to project future prevalence, which is more
useful for health service planning for cancer patients.
Studies of breast cancer prevalence in the United
States (USA) using SEER data have reported projected
increases in prevalence comparable to our results, with
the number of women with breast cancer in the USA ex-
pected to increase by an annual rate of 3.11% from 2010
to 2020 [3]. It is not surprising that these results are
similar, as the main factor in breast cancer prevalence
modelling is the incidence rate, and in both our study
and the USA study incidence rates were predicted to re-
main at the current high level in the foreseeable future
[31]. Also, the population age structures of the USA and
Australia are broadly similar [32], and this is another im-
portant contributor to prevalence estimates.
This study is unique in its inclusion of data on subse-
quent cancer spread and second breast cancers to allow
for the projection of prevalence according to phase of
care. These two groups of patients with distant metasta-
ses or a new primary breast cancer constitute over 1100
women who will require active cancer treatment in 2017
in NSW, so it is essential that they be included when es-
timating future prevalence to inform cancer care needs.
Furthermore, it is possible that due to the issue of in-
complete episode data the reported number of patients
with subsequent metastatic disease is an under estimate of
the true figure [15,33]. Data on cancer spread after initial
diagnosis are not routinely collected by population-based
cancer registries worldwide, but where possible the use of
such data in research is a useful step towards providing
clinically relevant information for patients, clinicians
and health policy makers. Our results also provide
some support for the ongoing surveillance of breast
cancer survivors given the observed numbers with
subsequent metastases from the first cancer and theer in NSW Australia in 2017 by phases of care and age
er survivors
69 years 70-84 years Total
881 (7.8%) 1296 (4.9%) 4965 (7.2%)
171 (51.8%) 9272 (35.2%) 31,974 (46.6%)
031 (37.9%) 14,947 (56.8%) 29,785 (43.4%)
336 (0.9%) 361 (1.4%) 774 (1.1%)
584 (1.6%) 449 (1.7%) 1122 (1.6%)
003 (54%) 26,325 (38%) 68,620 (100%)
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noting that these represented a modest proportion of
women living with breast cancer. Oncologists and
clinical researchers may be interested in our projected
increased proportion of older breast cancer survivors,
a group typically not included in clinical trials, and
might consider expanding age criteria for current and
future clinical trials.
Cancer prevalence is a function of cancer incidence
and survival. As indicated by our model, the number of
new breast cancer diagnoses will keep rising in the fu-
ture (although the rates had started to stabilise), and sur-
vival is likely to continue to show some improvement,
meaning that prevalence will inevitably also increase in
the future. Our assumptions of future incidence and sur-
vival trends appear to be reasonable as they were based
on 36 years of data and our understanding of the epi-
demiology of breast cancer in Australia. Our validation
using external mortality data suggests that our projec-
tions for incidence and survival are likely to be appropri-
ate (Figure 5). Most international studies, including
those from the UK, Europe and the USA, indicated an
increase in breast cancer prevalence in the future
[2,3,34]. Therefore, these projections are likely to be
relatively reliable, although as with all statistical predic-
tions some uncertainties will remain.
While we have attempted to provide a robust estima-
tion of breast cancer prevalence by phase of care we are
aware that there are several limitations to this study.
First, the PIAMOD software does not provide measures
of uncertainty for projections of relative survival, popu-
lation size and mortality, so we cannot assess the poten-
tial range of results. Second, not all changes in trends of
cancer incidence and survival can be fully captured by
our models, particularly for survival data (that even
10 years after diagnosis the probability of survival does
not reach that of the general population) [35,36]. How-
ever, different assumptions of future survival trends only
had a small impact on the predicted prevalence (data
not shown) because survival has less room for further
improvement (five-year relative survival being over 90%).
Third, we are aware that our projections are likely to
underestimate future prevalence because we did not in-
clude cases aged 85 years or over (approximately 4% of
the total patient population). We were unable to include
these older cases because the PIAMOD software can
only provide estimates for 1-year age groups, while the
population was grouped as 85 years and over. Finally, al-
though the phases of care definition used here is useful
to infer future health care needs, the phases are often
not as discrete as the categories imply, and some of
them are cross-cutting, so that there are actually many
different possible pathways cancer patients may experi-
ence from diagnosis to survival or end of life.Conclusions
As the Australian population ages the number of women
living with breast cancer will increase, and consequently
demands on health care services will also increase. In
order to ensure adequate access to quality care for all fu-
ture patients, careful planning and development of a
healthcare system able to respond to this increased de-
mand is required. Such preparation is critical, especially
as the consequences of not providing appropriate cancer
care and follow-up are already becoming apparent [37],
and indeed, any shortfall in the oncology workforce
could threaten the quality of patient care and safety [38].
In addition, a major investment in the infrastructure re-
quired to deliver cancer care is needed [39], and the rap-
idly increasing cost of cancer care must also be
considered. A 27% increase in the national cost of cancer
care was projected from 2010 to 2020 in the USA, with
the largest increases being for female breast cancer and
prostate cancer [3]. Australia must begin to consider
how it will afford to provide quality cancer care for a
large and increasing cancer survivor population in the
future.
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